GO:0019962 type I interferon binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019962 (type I interferon binding) is a molecular function defined as binding to any type I interferon, including IFN-alpha, IFN-beta, IFN-delta, IFN-epsilon, IFN-zeta, IFN-kappa, IFN-tau, and IFN-omega.
• Type I interferon binding is the first step in interferon signaling and is essential for antiviral defense, immune regulation, and interferonopathies such as Aicardi-Goutieres syndrome and systemic lupus erythematosus [3,7,8].
• Key proteins that bind type I interferons include the interferon receptors IFNAR1 and IFNAR2, which form the core signaling complex, as well as regulatory proteins such as ZBP1, ADAR1, and DHX58 that modulate interferon induction and responses [1,4,5].
• Dysregulation of type I interferon binding and downstream signaling is linked to autoinflammatory and autoimmune diseases, including pediatric SLE and Aicardi-Goutieres syndrome [7,8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are powerful tools to dissect the causal roles of genes involved in type I interferon binding and signaling [2,4,5].
• Studying type I interferon binding requires integrated methods such as surface plasmon resonance, co-immunoprecipitation, RNA-seq, and reporter assays to measure binding affinity and downstream transcriptional responses [1,2,6].
Description
Type I interferon binding (GO:0019962) is a molecular function that describes the physical interaction between a protein and any member of the type I interferon family, which includes interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega. This binding event is the initial step in type I interferon signaling, a central pathway for antiviral immunity and immune homeostasis. The QuickGO definition captures this broad specificity, reflecting the evolutionary diversity of type I interferons and their shared receptors. Researchers study this function to understand how cells sense and respond to interferons, and how defects in these interactions contribute to human disease. For example, ZBP1 senses Brucella abortus DNA and triggers type I interferon signaling, highlighting the role of nucleic acid sensing in interferon binding and downstream responses. Similarly, cyclic GMP-AMP synthase (cGAS) is a cytosolic DNA sensor that activates the type I interferon pathway, demonstrating the link between pathogen detection and interferon binding. These examples underscore the importance of type I interferon binding in host defense and autoimmunity.
type I interferon binding At A Glance
| GO ID | GO:0019962 |
|---|---|
| GO term | type I interferon binding |
| Ontology | molecular_function |
| Synonym | interferon-alpha/beta binding, interferon-alpha binding, interferon-beta binding, interferon-delta binding, interferon-epsilon binding, interferon-kappa binding, interferon-omega binding, interferon-tau binding, interferon-zeta binding, type I IFN binding |
| Major function | Binding to type I interferons to initiate signaling and immune responses |
| Definition | Binding to a type I interferon. Type I interferons include the interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega gene families. |
| Related pathways | Type I interferon signaling, antiviral defense, innate immune sensing |
| Disease relevance | Systemic lupus erythematosus, Aicardi-Goutieres syndrome, autoinflammatory disorders |
What Is GO:0019962?
In our own words, GO:0019962 (type I interferon binding) refers to the ability of a protein or molecular complex to selectively and non-covalently interact with a type I interferon cytokine. This includes all subtypes: interferon-alpha, beta, delta, epsilon, zeta, kappa, tau, and omega. The binding can occur on the cell surface, as with the interferon receptors IFNAR1 and IFNAR2, or intracellularly, as with sensors and regulatory proteins. This function is a prerequisite for initiating signaling cascades that lead to transcriptional activation of interferon-stimulated genes (ISGs) and the establishment of an antiviral state [1,2].
Why Is type I interferon binding Important in Cell Biology?
Type I interferon binding is critically important because it governs the first step of a signaling axis that protects against viral infections and shapes immune responses. Dysregulation of this binding can lead to uncontrolled interferon production, which is a hallmark of interferonopathies such as Aicardi-Goutieres syndrome and systemic lupus erythematosus [3,7,8]. Understanding the molecular details of type I interferon binding enables the development of targeted therapies and diagnostic tools for these diseases.
• Initiates antiviral defense by triggering JAK-STAT signaling and ISG expression [1,2].
• Central to innate immune sensing of nucleic acids via cGAS-STING and ZBP1 pathways [1,2].
• Dysregulated in autoimmune diseases like systemic lupus erythematosus, where interferon signatures are prominent [3,7].
• Mutations in ADAR1 cause Aicardi-Goutieres syndrome with a type I interferon signature, linking binding and signaling to disease.
• IRF-7 acts as a master regulator of type I interferon-dependent immune responses, amplifying interferon production.
• MATR3 promotes liver cancer progression by suppressing DHX58-mediated type I interferon response, showing cancer relevance.
• ZBP1 senses Brucella abortus DNA and triggers type I interferon signaling, illustrating pathogen-specific activation.
• ADAR1 averts fatal type I interferon induction by ZBP1, highlighting regulatory checkpoints.
• Pediatric systemic lupus erythematosus involves type I interferon pathway dysregulation, offering pediatric-specific insights.
• Therapeutic targeting of type I interferon binding and signaling is an active area in autoimmunity and oncology [3,5].
Molecular Mechanism of type I interferon binding
Interferon recognition and receptor engagement
In simple terms: Type I interferons bind to specific receptors on the cell surface, like a key fitting a lock.
Type I interferons, including IFN-alpha and IFN-beta, bind to the heterodimeric receptor composed of IFNAR1 and IFNAR2. This binding event is the defining molecular function of GO:0019962 and triggers a conformational change that activates associated JAK kinases. The specificity of binding is determined by the interferon subtype and receptor structure, as reviewed in the context of systemic lupus erythematosus pathogenesis. ZBP1 can also bind type I interferons indirectly by sensing DNA and inducing their expression, as shown for Brucella abortus DNA.
Intracellular sensing and interferon induction
In simple terms: Inside the cell, sensors detect foreign DNA and turn on interferon production, which then binds to receptors.
Cytosolic DNA sensors such as cGAS produce cyclic GMP-AMP (cGAMP) that activates STING, leading to type I interferon production. ZBP1 senses Brucella abortus DNA and triggers type I interferon signaling and unfolded protein response activation. ADAR1 editing of endogenous RNA prevents ZBP1-mediated fatal type I interferon induction, illustrating a regulatory checkpoint. These pathways converge on the production of type I interferons that then engage binding partners.
Signal amplification via IRF-7
In simple terms: A protein called IRF-7 acts as a master switch to boost interferon production.
IRF-7 is a master regulator of type I interferon-dependent immune responses, as demonstrated in mouse models where IRF-7 deficiency impairs interferon production. Upon interferon binding, signaling through JAK-STAT induces IRF-7 expression, creating a positive feedback loop that amplifies the antiviral response. This amplification is critical for effective pathogen clearance but must be tightly controlled to avoid autoimmunity.
Regulation by ADAR1 and ZBP1
In simple terms: ADAR1 prevents the immune system from attacking the body's own RNA, avoiding unwanted interferon responses.
ADAR1 averts fatal type I interferon induction by ZBP1, as shown in Adar1 knockout mice. Mutations in ADAR1 cause Aicardi-Goutieres syndrome, a disease with a type I interferon signature. This regulation ensures that self-RNA is not sensed as foreign, preventing chronic interferon binding and signaling. The balance between ZBP1 activation and ADAR1 suppression is crucial for immune homeostasis.
Tumor suppression of interferon response by MATR3
In simple terms: In liver cancer, a protein called MATR3 blocks a interferon response, helping tumors grow.
MATR3 promotes liver cancer progression by suppressing DHX58-mediated type I interferon response. DHX58 (also known as LGP2) is a RNA sensor that can enhance interferon production. By inhibiting DHX58, MATR3 reduces type I interferon binding and downstream signaling, facilitating immune evasion. This highlights how cancer cells can hijack interferon binding pathways.
Key Genes Involved in GO:0019962 type I interferon binding
The following genes and proteins are directly or indirectly involved in type I interferon binding and its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNAR1 | Type I interferon receptor subunit 1; binds interferons | Core receptor for interferon binding; target for knockout studies |
| IFNAR2 | Type I interferon receptor subunit 2; binds interferons | High-affinity receptor subunit; essential for signaling |
| ZBP1 | Senses DNA and triggers type I interferon signaling | Links DNA sensing to interferon binding; knockout models available |
| ADAR1 | RNA editing enzyme; prevents ZBP1-mediated interferon induction | Mutations cause Aicardi-Goutieres syndrome; key regulator [4,8] |
| DHX58 | RNA sensor that enhances type I interferon response | Suppressed by MATR3 in liver cancer |
| IRF-7 | Master regulator of type I interferon-dependent immune responses | Amplifies interferon production; knockout impairs responses |
| CGAS | Cytosolic DNA sensor; activates type I interferon pathway | Produces cGAMP to trigger interferon; knockout reduces interferon |
| STING1 | Adaptor in cGAS-STING pathway; induces type I interferon | Central to DNA sensing and interferon induction |
| IFNA1 | Interferon alpha 1; binds type I interferon receptor | Prototype type I interferon; used in binding assays |
| IFNB1 | Interferon beta 1; binds type I interferon receptor | Key antiviral cytokine; used in binding studies |
| IFNE | Interferon epsilon; binds type I interferon receptor | Mucosal interferon; less studied but relevant |
| IFNK | Interferon kappa; binds type I interferon receptor | Keratinocyte-derived interferon; role in skin immunity |
| IFNW1 | Interferon omega 1; binds type I interferon receptor | Functional in some species; potential model |
| JAK1 | Kinase activated upon interferon binding | Mediates signaling downstream of receptor binding |
| TYK2 | Kinase activated upon interferon binding | Essential for type I interferon signaling |
| STAT1 | Transcription factor activated by interferon binding | Drives ISG expression; knockout abolishes responses |
| STAT2 | Transcription factor activated by interferon binding | Forms ISGF3 with STAT1 and IRF9 |
| IRF9 | Part of ISGF3 complex; mediates ISG transcription | Downstream of interferon binding |
How Is type I interferon binding Regulated?
Type I interferon binding and signaling are tightly regulated at multiple levels. ADAR1 editing of endogenous RNA prevents ZBP1 from sensing self-RNA and triggering fatal type I interferon induction. IRF-7 acts as a master regulator that amplifies type I interferon-dependent immune responses through a positive feedback loop. In cancer, MATR3 suppresses DHX58-mediated type I interferon response, promoting tumor progression. Additionally, cGAS-STING pathway activation by cytosolic DNA leads to interferon production, which then binds receptors in an autocrine or paracrine manner. These regulatory mechanisms ensure balanced interferon responses and prevent autoimmunity.
type I interferon binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADAR1 | Aicardi-Goutieres syndrome; type I interferon signature | Knockout or point mutation in cell lines; measure ISG expression |
| IFNAR1 | SLE; interferonopathies | Knockout cells to abolish interferon binding; test signaling |
| ZBP1 | Autoinflammation; Brucella infection | Knockout macrophages; measure interferon induction |
| MATR3 | Liver cancer progression | Overexpression in hepatoma cells; assess DHX58 and interferon response |
| IRF-7 | Immunodeficiency; impaired interferon responses | Knockout mice or cells; challenge with viral mimics |
Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus is characterized by a prominent type I interferon signature, and dysregulated interferon binding and signaling contribute to pathogenesis. Pediatric SLE also shows type I interferon pathway dysregulation, with implications for diagnosis and treatment. Therapeutic strategies targeting type I interferon binding or downstream signaling are under investigation.
Aicardi-Goutieres syndrome (AGS)
Mutations in ADAR1 cause Aicardi-Goutieres syndrome, an autoinflammatory disorder associated with a type I interferon signature. Loss of ADAR1 function leads to ZBP1-mediated fatal type I interferon induction, demonstrating the critical role of interferon binding regulation. AGS serves as a monogenic model for understanding interferonopathies.
Cancer
MATR3 promotes liver cancer progression by suppressing DHX58-mediated type I interferon response, indicating that interferon binding pathways can be co-opted by tumors. Enhancing type I interferon binding and signaling is a potential immunotherapeutic strategy. Conversely, chronic interferon signaling can promote immune exhaustion, necessitating careful modulation.
Infectious diseases
ZBP1 senses Brucella abortus DNA and triggers type I interferon signaling, highlighting the role of interferon binding in bacterial infection. cGAS is a cytosolic DNA sensor that activates the type I interferon pathway, important for antiviral defense. Understanding these interactions can inform vaccine and therapeutic development.
From type I interferon binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IFNAR1 mediate type I interferon binding? | IFNAR1 knockout cell line (e.g., HEK293) via CRISPR |
| Does a point mutation in ADAR1 alter interferon induction? | ADAR1 point-mutation knock-in cells; measure ISG expression |
| Can tagged IFNAR2 be used to pull down interferons? | Knock-in of epitope-tagged IFNAR2; co-IP with IFN-alpha |
| Does overexpression of MATR3 suppress interferon response? | MATR3 overexpression in liver cancer cells; RNA-seq |
| Is IRF-7 required for interferon amplification? | IRF-7 knockout cells; stimulate with IFN and measure ISGs |
| Does ZBP1 sense Brucella DNA to trigger interferon? | ZBP1 knockout macrophages; infection with Brucella |
How to Study the type I interferon binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Measure IFN-alpha binding to IFNAR2 |
| Co-immunoprecipitation | Physical interaction in cell lysates | Confirm ZBP1-IFN binding in infected cells |
| RNA-seq | Global transcriptional changes | Assess ISG signature after interferon treatment |
| ISRE-luciferase reporter | Interferon pathway activation | Screen for regulators of type I interferon binding |
| CRISPR knockout screen | Genes required for interferon response | Identify novel binding partners or signaling components |
| Proximity labeling (BioID) | Interactome in living cells | Map proteins near IFNAR1 upon interferon binding |
| Flow cytometry | Cell surface binding of labeled interferon | Quantify IFNAR1 levels and binding capacity |
Binding assays (SPR, BLI, co-IP)
Surface plasmon resonance (SPR) and biolayer interferometry (BLI) measure real-time binding affinity between type I interferons and their receptors or binding proteins. Co-immunoprecipitation (co-IP) followed by western blot can confirm physical interactions in cell lysates. These methods directly assess GO:0019962 activity and are essential for validating binding specificity.
Transcriptional readouts (RNA-seq, qPCR)
RNA sequencing and quantitative PCR measure expression of interferon-stimulated genes (ISGs) downstream of type I interferon binding. This provides a functional readout of pathway activation. For example, ISG signatures are used to diagnose interferonopathies like AGS and SLE [7,8].
Reporter assays and CRISPR screens
Luciferase reporters driven by interferon-stimulated response elements (ISRE) quantify pathway activation. Genome-wide CRISPR knockout screens can identify genes required for type I interferon binding and signaling, as demonstrated for cGAS-STING and ZBP1 pathways [1,2].
Proteomics and interactomics
Affinity purification mass spectrometry (AP-MS) can identify novel type I interferon binding partners. Proximity labeling (BioID) can map interactomes in living cells. These approaches expand the list of proteins that may execute GO:0019962.
How CRISPR Can Be Used to Study GO:0019962 type I interferon binding
Knockout
CRISPR knockout of genes such as IFNAR1, IFNAR2, or ZBP1 abolishes type I interferon binding or downstream signaling, providing causal evidence. For example, ZBP1 knockout macrophages fail to respond to Brucella abortus DNA with interferon induction. Knockout of ADAR1 leads to fatal type I interferon induction, demonstrating its regulatory role.
Point Mutation
Point mutations can mimic disease-associated variants, such as those in ADAR1 found in Aicardi-Goutieres syndrome. CRISPR-mediated point mutation knock-in allows precise modeling of binding interface residues in IFNAR1 or IFNAR2 to dissect affinity and specificity. This approach is ideal for studying structure-function relationships.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) into endogenous IFNAR1 or IFNAR2 enables affinity purification and proteomic analysis of the binding complex. Knock-in of reporter genes (e.g., luciferase) under interferon-stimulated promoters allows real-time monitoring of pathway activation. These models are valuable for drug discovery.
Overexpression
Overexpression of type I interferons or their receptors can amplify binding and signaling, useful for studying gain-of-function effects. For example, overexpression of MATR3 suppresses DHX58-mediated interferon response, promoting cancer progression. Overexpression models help identify dominant-negative or hyperactive phenotypes.
How EDITGENE Supports type I interferon binding Research
Researchers studying type I interferon binding-related genes often need to determine whether a candidate gene is causally involved in interferon sensing, signaling, or regulation. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for type I interferon binding research.
Frequently Asked Questions About type I interferon binding
What is type I interferon binding?
Type I interferon binding (GO:0019962) is the molecular function of selectively interacting with type I interferons such as IFN-alpha and IFN-beta, initiating signaling.
What genes are involved in type I interferon binding?
Key genes include IFNAR1, IFNAR2, ZBP1, ADAR1, DHX58, IRF-7, CGAS, and STING1, among others [1,2,4,5,6].
What diseases are associated with type I interferon binding?
Dysregulation is linked to systemic lupus erythematosus, Aicardi-Goutieres syndrome, and some cancers [3,5,7,8].
How is type I interferon binding studied?
Methods include surface plasmon resonance, co-immunoprecipitation, RNA-seq, and CRISPR screens [1,2,6].
What is the role of ZBP1 in type I interferon binding?
ZBP1 senses DNA and triggers type I interferon signaling, as shown for Brucella abortus.
How does ADAR1 regulate type I interferon binding?
ADAR1 prevents ZBP1-mediated fatal type I interferon induction by editing endogenous RNA.
What is the link between IRF-7 and type I interferon binding?
IRF-7 is a master regulator that amplifies type I interferon-dependent immune responses.
Can CRISPR be used to study type I interferon binding?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to dissect gene function in this pathway [2,4,5].
What is the cGAS-STING pathway's role in type I interferon binding?
cGAS senses cytosolic DNA and produces cGAMP to activate STING, leading to type I interferon production and subsequent binding.
What are the synonyms for type I interferon binding?
Synonyms include interferon-alpha/beta binding, interferon-alpha binding, interferon-beta binding, and type I IFN binding, among others.
Conclusion
Type I interferon binding (GO:0019962) is a fundamental molecular function that initiates antiviral and immune-regulatory signaling. Its dysregulation underlies autoimmune and autoinflammatory diseases such as SLE and AGS, and it plays complex roles in cancer and infection. Continued research using CRISPR models and advanced binding assays will illuminate new therapeutic opportunities.
References
- 1. Gomes MTR et al.. 2024. ZBP1 senses Brucella abortus DNA triggering type I interferon signaling pathway and unfolded protein response activation.. Front Immunol 15:1511949 PMID: 39850894
- 2. Sun L et al.. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.. Science 339(6121):786-91 PMID: 23258413
- 3. Crow MK. 2023. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets.. Ann Rheum Dis 82(8):999-1014 PMID: 36792346
- 4. Jiao H et al.. 2022. ADAR1 averts fatal type I interferon induction by ZBP1.. Nature 607(7920):776-783 PMID: 35859176
- 5. Xiao Z et al.. 2024. MATR3 promotes liver cancer progression by suppressing DHX58-mediated type I interferon response.. Cancer Lett 604:217231 PMID: 39276912
- 6. Honda K et al.. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses.. Nature 434(7034):772-7 PMID: 15800576
- 7. Zhou Y et al.. 2024. Type I interferon pathway in pediatric systemic lupus erythematosus.. World J Pediatr 20(7):653-668 PMID: 38914753
- 8. Rice GI et al.. 2012. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature.. Nat Genet 44(11):1243-8 PMID: 23001123
